These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 23343913)

  • 1. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis.
    Shubber Z; Calmy A; Andrieux-Meyer I; Vitoria M; Renaud-Théry F; Shaffer N; Hargreaves S; Mills EJ; Ford N
    AIDS; 2013 Jun; 27(9):1403-12. PubMed ID: 23343913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative durability of nevirapine versus efavirenz in first-line regimens during the first year of initiating antiretroviral therapy among Swaziland HIV-infected adults.
    Takuva S; Evans D; Zuma K; Okello V; Louwagie G
    Pan Afr Med J; 2013; 15():5. PubMed ID: 23847702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw LC; Irlam JH; Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Dec; (12):CD004246. PubMed ID: 21154355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nevirapine-related adverse events among children switched from efavirenz to nevirapine as compared to children who were started on nevirapine-based antiretroviral therapy directly.
    Sanjeeva GN; Sukanya V; Pavithra HB; Dodderi SK; Rewari BB; Govindaraj M; Shivananda S; Premalatha R
    AIDS Care; 2015; 27(5):655-9. PubMed ID: 25517472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
    Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
    Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials.
    Ford N; Shubber Z; Pozniak A; Vitoria M; Doherty M; Kirby C; Calmy A
    J Acquir Immune Defic Syndr; 2015 Aug; 69(4):422-9. PubMed ID: 25850607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
    Manosuthi W; Mankatitham W; Lueangniyomkul A; Chimsuntorn S; Sungkanuparph S
    HIV Med; 2008 May; 9(5):294-9. PubMed ID: 18400076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine or efavirenz in Uganda: a prospective non-randomized study.
    Mwesigire DM; Wu AW; Martin F; Katamba A; Seeley J
    BMC Health Serv Res; 2015 Jul; 15():292. PubMed ID: 26216221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.
    Swaminathan S; Padmapriyadarsini C; Venkatesan P; Narendran G; Ramesh Kumar S; Iliayas S; Menon PA; Selvaraju S; Pooranagangadevi NP; Bhavani PK; Ponnuraja C; Dilip M; Ramachandran R
    Clin Infect Dis; 2011 Oct; 53(7):716-24. PubMed ID: 21890776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and tolerance of efavirenz- and nevirapine-containing regimens in adult HIV type 1 Senegalese patients.
    de Beaudrap P; Etard JF; Guèye FN; Guèye M; Landman R; Girard PM; Sow PS; Ndoye I; Delaporte E;
    AIDS Res Hum Retroviruses; 2008 Jun; 24(6):753-60. PubMed ID: 18507521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of efavirenz-based regimens in young HIV-infected children treated for tuberculosis: a treatment option for resource-limited settings.
    van Dijk JH; Sutcliffe CG; Hamangaba F; Bositis C; Watson DC; Moss WJ
    PLoS One; 2013; 8(1):e55111. PubMed ID: 23372824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-nucleoside reverse transcriptase inhibitor levels among HIV-exposed uninfected infants at the time of HIV PCR testing - findings from a tertiary healthcare facility in Pretoria, South Africa.
    Mazanderani AH; Murray TY; Sherman GG; Snyman T; George J; Avenant T; Goga AE; Pepper MS; du Plessis N
    J Int AIDS Soc; 2019 Jun; 22(6):e25284. PubMed ID: 31215757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatotoxicity in patients prescribed efavirenz or nevirapine.
    Brück S; Witte S; Brust J; Schuster D; Mosthaf F; Procaccianti M; Rump JA; Klinker H; Petzold D; Hartmann M
    Eur J Med Res; 2008 Jul; 13(7):343-8. PubMed ID: 18700192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing the effectiveness of efavirenz and nevirapine for first-line antiretroviral therapy in a South African multicentre cohort.
    Bock P; Fatti G; Grimwood A
    Int Health; 2013 Jun; 5(2):132-8. PubMed ID: 24030113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis.
    Pillay P; Ford N; Shubber Z; Ferrand RA
    PLoS One; 2013; 8(7):e68995. PubMed ID: 23894391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
    van Leth F; Phanuphak P; Ruxrungtham K; Baraldi E; Miller S; Gazzard B; Cahn P; Lalloo UG; van der Westhuizen IP; Malan DR; Johnson MA; Santos BR; Mulcahy F; Wood R; Levi GC; Reboredo G; Squires K; Cassetti I; Petit D; Raffi F; Katlama C; Murphy RL; Horban A; Dam JP; Hassink E; van Leeuwen R; Robinson P; Wit FW; Lange JM;
    Lancet; 2004 Apr; 363(9417):1253-63. PubMed ID: 15094269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are adverse events of nevirapine and efavirenz related to plasma concentrations?
    Kappelhoff BS; van Leth F; Robinson PA; MacGregor TR; Baraldi E; Montella F; Uip DE; Thompson MA; Russell DB; Lange JM; Beijnen JH; Huitema AD;
    Antivir Ther; 2005; 10(4):489-98. PubMed ID: 16038474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons.
    van den Berg-Wolf M; Hullsiek KH; Peng G; Kozal MJ; Novak RM; Chen L; Crane LR; Macarthur RD;
    HIV Clin Trials; 2008; 9(5):324-36. PubMed ID: 18977721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
    Sulkowski MS; Thomas DL; Mehta SH; Chaisson RE; Moore RD
    Hepatology; 2002 Jan; 35(1):182-9. PubMed ID: 11786975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.